Rodney J. Hicks

1991–2025 年に発表

226
論文数
31,635
被引用数
98
h 指数
220
i10 指数

被引用数

Rodney J. Hicks の年別被引用数1984 年: 被引用 5 件1992 年: 被引用 5 件1993 年: 被引用 3 件1994 年: 被引用 6 件1995 年: 被引用 3 件1996 年: 被引用 13 件1997 年: 被引用 17 件1998 年: 被引用 5 件1999 年: 被引用 3 件2000 年: 被引用 1 件2001 年: 被引用 11 件2002 年: 被引用 32 件2003 年: 被引用 66 件2004 年: 被引用 74 件2005 年: 被引用 68 件2006 年: 被引用 103 件2007 年: 被引用 155 件2008 年: 被引用 123 件2009 年: 被引用 135 件2010 年: 被引用 113 件2011 年: 被引用 128 件2012 年: 被引用 144 件2013 年: 被引用 139 件2014 年: 被引用 206 件2015 年: 被引用 170 件2016 年: 被引用 193 件2017 年: 被引用 225 件2018 年: 被引用 275 件2019 年: 被引用 875 件2020 年: 被引用 1,202 件2021 年: 被引用 1,413 件2022 年: 被引用 1,070 件2023 年: 被引用 844 件2024 年: 被引用 1,428 件2025 年: 被引用 641 件2026 年: 被引用 12 件1985〜1991 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,777 件、この内訳の 20.7%ドイツ: 引用元論文 1,144 件、この内訳の 8.5%オーストラリア: 引用元論文 886 件、この内訳の 6.6%中国: 引用元論文 879 件、この内訳の 6.5%イタリア: 引用元論文 873 件、この内訳の 6.5%イギリス: 引用元論文 814 件、この内訳の 6.1%オランダ: 引用元論文 651 件、この内訳の 4.8%フランス: 引用元論文 632 件、この内訳の 4.7%カナダ: 引用元論文 440 件、この内訳の 3.3%スイス: 引用元論文 434 件、この内訳の 3.2%スペイン: 引用元論文 323 件、この内訳の 2.4%ベルギー: 引用元論文 298 件、この内訳の 2.2%
0%20.7%その他 24.5%

分野

  • Medicine81.3%
  • Biochemistry, Genetics and Molecular Biology12.5%
  • Immunology and Microbiology1.1%
  • Engineering1%
  • Neuroscience0.8%
  • Physics and Astronomy0.7%
  • その他2.6%

トピック

  • Radiopharmaceutical Chemistry and Applications6.7%
  • Prostate Cancer Treatment and Research6.6%
  • Medical Imaging Techniques and Applications5.2%
  • Prostate Cancer Diagnosis and Treatment3.7%
  • Neuroendocrine Tumor Research Advances3.5%
  • Lymphoma Diagnosis and Treatment3.4%
  • その他70.9%

共著者

全論文

検索で開く
  1. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2020 被引用: 1,962

  2. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

    著者: , , , , , , , , , , , , , , - The Lancet Oncology 2018 被引用: 1,143

  3. Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes

    著者: , , , , , , , , , , , , , , - Journal of Nuclear Medicine 2018 被引用: 486

  4. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeffrey C. Goh, Alex Guminski, Anis Hamid, Mohammad B. Haskali, Rodney J. Hicks, Edward Hsiao, Amir Iravani, Anthony M. Joshua, Ian Kirkwood, Grace Kong, Edmond M. Kwan, Ailsa Langford, Nicola Jane Lawrence, Sze-Ting Lee, Jeremy Lewin, Peter Lin, Andrew Martin, William M. McDonald, Margaret McJannett, Kate Moodie, Declan G. Murphy, Siobhan Ng, David A. Pattison, Izabella Pokorski, Shakher Ramdave, Aravind S. Ravi Kumar, Andrew Redfern, Natalie Rutherford, Javad Saghebi, Shahneen Sandhu, Andrew M. Scott, Lavinia Spain, Martin R. Stockler, Shalini Subramaniam, Thean Hsiang Tan, Sue Ping Thang, Ben Tran, Roslyn E. Wallace, Andrew Weickhardt, Scott Williams, Sonia Yip, Alison Y. Zhang, Sonia Yip, Alison Y. Zhang - The Lancet Oncology 2022 被引用: 266

  5. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - European Journal of Nuclear Medicine and Molecular Imaging 2023 被引用: 255

  6. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group

    著者: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2014 被引用: 1,648

  7. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer

    著者: , , , , , , , , , , , , , , , , , , , , - Journal of Nuclear Medicine 2019 被引用: 286

  8. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma

    著者: , , , , , , , , , , , , , , - European Journal of Nuclear Medicine and Molecular Imaging 2019 被引用: 370

  9. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2019 被引用: 190

  10. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - European Journal of Nuclear Medicine and Molecular Imaging 2019 被引用: 383

  11. Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors

    著者: , , , , - Journal of Nuclear Medicine 2019 被引用: 137

  12. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , James C. Yao - European Journal of Cancer 2021 被引用: 242

  13. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

    著者: , , , , , , , , , , , , , , - Neuroendocrinology 2017 被引用: 331

  14. International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Reviews Endocrinology 2021 被引用: 163

  15. LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 78

  16. Somatostatin Receptor Imaging with68Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation

    著者: , , - Radiographics 2015 被引用: 556

  17. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls

    著者: , , , - Radiographics 2018 被引用: 378

  18. 64Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Nuclear Medicine 2018 被引用: 147

  19. FAPI PET/CT: Will It End the Hegemony of 18F-FDG in Oncology?

    著者: , , , , - Journal of Nuclear Medicine 2020 被引用: 129

  20. Delivering affordable cancer care in high-income countries

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Paul Catchpole, David Taylor, Jan Geißler, Nancy Brinker, David Meltzer, David Kerr, Matti Aapro - The Lancet Oncology 2011 被引用: 714

  21. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Blood 2015 被引用: 340

  22. Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617

    著者: , , , , , , , , , , , - European Journal of Nuclear Medicine and Molecular Imaging 2020 被引用: 155

  23. Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study

    著者: , , , , , , , , , , , , , , , , , , - Cancer Discovery 2022 被引用: 55

  24. A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study

    著者: , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2023 被引用: 52